The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1719
January 6, 2025
View Complete Issue         Table of Contents 2019 
Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease
January 6, 2025 (Issue: 1719)
Vyalev (Abbvie), a solution for continuous subcutaneous infusion containing the prodrugs foscarbidopa and foslevodopa, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease
Article code: 1719c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.